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ABSTRACT
Anti-microRNA (miRNA) oligonucleotides (AMOs)
with 2′-O-Methyl (2′OMe) residues are commonly
used to study miRNA function and can achieve high
potency, with low cytotoxicity. Not withstanding this,
we demonstrate the sequence-dependent capacity of
2′OMe AMOs to inhibit Toll-like receptor (TLR) 7 and 8
sensing of immunostimulatory RNA, independent of
their miRNA-targeting function. Through a screen of
29 AMOs targeting common miRNAs, we found a sub-
set of sequences highly inhibitory to TLR7 sensing
in mouse macrophages. Interspecies conservation of
this inhibitory activity was confirmed on TLR7/8 ac-
tivity in human peripheral blood mononuclear cells.
Significantly, we identified a core motif governing the
inhibitory activity of these AMOs, which is present
in more than 50 AMOs targeted to human miRNAs in
miRBaseV20. DNA/locked nucleic acids (LNA) AMOs
synthesized with a phosphorothioate backbone also
inhibited TLR7 sensing in a sequence-dependent
manner, demonstrating that the off-target effects of
AMOs are not restricted to 2′OMe modification. Taken
together, our work establishes the potential for off-
target effects of AMOs on TLR7/8 function, which
should be taken into account in their therapeutic de-
velopment and in vivo application.
INTRODUCTION
MicroRNAs (miRNAs) are short single-stranded RNAs
(ssRNAs) of ∼21–23 nucleotides that are involved in most
regulatory processes necessary for cellular function. These
small RNAs fine-tune gene expression through the re-
cruitment of the RNA-induced silencing complex (RISC)
to messenger RNA (mRNA) sequences with some degree
of complementarity (1). Recruitment of miRNA-RISC to
target mRNA sites results in decreased protein synthe-
sis through translational repression and mRNA destabi-
lization (2,3). Because of their ability to bind cognate se-
quences, the effect of miRNAs on target mRNAs can be di-
rectly inhibited through the use of steric antisense oligonu-
cleotides (ASOs) with high affinity for specific miRNAs (4).
ASOs have been used for more than three decades to
antagonize mRNA expression and were rapidly adapted
to block miRNAs following the rapid expansion of
the miRNA field (5,6). Building on knowledge from
ASOs, anti-miRNA oligonucleotides (AMOs) bearing 2′-
O-Methyl (2′OMe) ribose modification were shown to de-
crease RISC activity and block miRNA activity (5,6).
2′OMe modification of RNA is common in the field of
ASOs for its imparting of nuclease resistance and increased
Tm, conferring higher binding affinity for complementary
RNA. To date, 2′OMe-modified AMOs remain one of the
most widely used tools to dissect miRNA function due to
their relatively high affinity for target miRNAs, lack of sig-
nificant toxicity and low cost of synthesis (7).
In addition to the beneficial use of 2′OMe in ASOs
and AMOs, this ribose modification mimics that of en-
dogenous capped mRNAs with the added benefit of de-
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creased immunogenicity (8,9). As such, RNA sensing by in-
nate immune sensors, such as Toll-like receptor 7 (TLR7)
is strongly decreased by 2′OMe incorporation in other-
wise immunostimulatory oligonucleotides (9–12). In fact,
2′OMe oligonucleotides appear to bind more avidly to
TLR7, thereby antagonizing sensing of other immunostim-
ulatory RNAs (13).
TLR7 and TLR8 are specialized in the detection of
pathogenic RNA by immune phagocytes, including plas-
macytoid dendritic cells and macrophages. Their activation
leads to the induction of a potent immune response me-
diated by pro-inflammatory cytokines, including interferon
alpha (IFN-) and tumour necrosis factor alpha (TNF-)
(14). This innate immune response is essential for mount-
ing an appropriate adaptive immune response to viral in-
fections, such as retroviruses or influenza, and bacterial in-
fections (15–18). Importantly, TLR7 and TLR8 are not ac-
tivated by all RNAs equally, and uridine-rich sequences
are more immunostimulatory than other sequences (19,20).
In addition, structural variations in the RNAs can affect
TLR7/8 sensing, making it difficult to predict which RNA
sequences are immunostimulatory (20,21). While the direct
inhibitory effect of as few as one 2′OMe residue incorpo-
rated within otherwise immunostimulatory RNAs has been
described (9,13,17,22), it is not known whether RNAs that
are fully 2′OMe-modified have sequence-dependent effects
on the sensing of immunostimulatory pathogenic RNA.
Nonetheless, it has previously been reported that incorpo-
ration of 2′OMe cytidine residues in RNA did not inhibit
TLR7/8 sensing (10,22). This suggests that cytidine-rich
2′OMe RNAs might have less inhibitory activity compared
to 2′OMe sequences of similar length with only a few cy-
tidines.
Here, while originally aiming at defining the regulatory
roles of the miR-17∼92 cluster of miRNAs in TLR7 sens-
ing in mouse macrophages, we observed a strong off-target
effect from our non-targeting control 2′OMe AMO, indica-
tive of sequence-dependent activity of 2′OMe AMOs on
TLR7/8 sensing. We demonstrate that AMOs that are fully
2′OMe-modified inhibit TLR7/8 sensing in a sequence-
dependent manner, independent of their miRNA-targeting
function. We establish that this effect relies on an in-
hibitory motif present in more than 50 miRNAAMOs, and
that LNA/DNA phosphorothioate AMOs can also inhibit
TLR7 in a sequence-dependent manner.
MATERIALS AND METHODS
Ethics statement
The use of animals and experimental procedures were ap-
proved by Monash Medical Centre Ethics Committee un-
der reference MMCA 2011/25.
Cell isolation and culture
miR-17∼92flox/flox mice (Jax mice stock 8458 – on a mixed
C57BL/6 and 129S4 background) harbouring loxP sites
on each side of the miR-17∼92 cluster (Mir17, Mir18,
Mir19a, Mir20a, Mir19b-1, Mir92–1) (23), were bred to
LysMCremice (kind gift fromDr. Irmgard Fo¨rster, LIMES
Institute, Bonn, Germany) expressing the Cre protein
from the myeloid-specific lysozyme 2 gene (Lyz2) pro-
moter (24). Primary bone marrow extraction and differ-
entiation to generate bone marrow-derived macrophages
(BMMs) were carried out following standard procedures.
Briefly, femurs from wild-type (WT) C57BL/6 and miR-
17∼92flox/flox × LysMCre mice were flushed with Dul-
becco’s modified Eagle’s medium (DMEM) complemented
with 1× antibiotic/antimycotic and 10% fetal bovine serum
(FBS) (completeDMEM), and cells were plated in complete
DMEM supplemented with 20% L-929 cell-conditioned
medium in T75-treated flasks for 6 days at 37◦C in a 5%
CO2 atmosphere (and rinsed with fresh medium on day
3). On day 6, the cells were collected and plated at 80
000 cells per well of a 96-well plate in 150 l DMEM
complete with L-929 cell-conditioned medium, and incu-
bated overnight prior to stimulation on day 7. Human
blood was collected from healthy donors in heparin-treated
tubes. Peripheral blood mononuclear cells (PBMCs) were
purified with Ficoll-Paque plus (GE Healthcare) as previ-
ously reported (25). PBMCs were plated at 200 000 per
well of a 96-well plate in 150 l of RPMI 1640 plus L-
glutaminemedium (Life Technologies), complementedwith
1× antibiotic/antimycotic and 10% FBS (Life Technolo-
gies), referred to as complete RPMI. The cells were in-
cubated for 2–4 h at 37◦C in 5% CO2 atmosphere be-
fore transfection with AMOs and stimulation by TLR
agonists. HEK293 TLR7 and TLR9 cells stably express-
ing human TLR7 or 9 were purchased from Invivogen
(293XL/hTLR7-HA and 293XL/hTLR9-HA) and main-
tained in complete DMEM supplemented with 10 g/ml
blasticidin.
Synthetic RNAs/AMOs and TLR ligands for stimulation of
cells
All synthetic RNAs were synthesized by Integrated DNA
Technologies (IDT). Immunostimulatory B-406AS-1
(UAAUUGGCGUCUGGCCUUCUU) (20) and -
Gal-656-REV (AAAUCGCUGAUUUGUGUAGUU)
(12), and non-stimulatory control RD (UAACACGC-
GACAGGCCAACUU) ssRNAs with no backbone
modification were resuspended in duplex buffer (100 mM
potassium acetate, 30 mM HEPES, pH 7.5, DNase–
RNase-free H2O) to 80 M. AMOs complementary to
human miRNAs were resuspended in sterile RNase-free
TE buffer (Life Technologies) to 4 M. 2′OMe AMOs
were synthesized with 2′OMe groups (‘M’), phosphodiester
linkages (unless otherwise noted) and a non-nucleotide
napthyl-azo group chemical modifier (dubbed ‘ZEN’- ‘z’)
near both ends (MzMMMMMMMMMMMMMMMz),
increasing potency at low nanomolar concentrations
(7) (Supplementary Table S1). LNA/DNA AMOs were
synthesized with phosphorothioate linkages, as detailed in
Supplementary Table S1. AMOs and ssRNAs were trans-
fected with DOTAP (Roche) and pure RPMI in biological
triplicate, as previously described (20–21,25). The ratios of
DOTAP to RNA (at 80 M) were as follows: 3.5 g/l
of ssRNA in BMMs and 5 g/l of ssRNA in PBMCs.
DOTAP-complexed AMOs were added 30–45 min before
the addition of other TLR ligands or DOTAP-complexed
immunostimulatory ssRNA. Following stimulation, the
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samples were incubated overnight for 16–18 h before
cytokine measurement by enzyme-linked immunosorbent
assay (ELISA). R848 (chemical TLR7/8 agonist), naked
polyI:C (TLR3 agonist) and ODN 2006 (human TLR9 ag-
onist) (Invivogen) were directly added to medium to a final
concentration of 1–2 g/ml (R848), 20 g/ml (polyI:C)
or 400 nM (ODN 2006), or as otherwise noted. ‘Mock’
condition refers to DOTAP only treatment. Stimulations
were carried out in biological triplicate in all experiments.
Detection of cytokines
Human TNF- and mouse TNF- were measured using
BD OptEIA ELISA sets, according to the manufacturer’s
instructions (BD Biosciences). Human IFN- detection
was carried out as previously reported (26). Tetramethyl-
benzidine substrate (Sigma Aldrich) was used for quan-
tification of the cytokines on a Fluostar OPTIMA (BMG
LABTECH) plate-reader.
Low-density miRNA arrays
TaqMan R© Array Rodent MicroRNAs (A Cards v2.0, Life
Technologies) were used for the estimation ofmiRNAabun-
dance in BMMs. Total RNA containing small RNAs was
purified from BMMs using the mirVana miRNA isola-
tion kit (Life Technologies). Briefly, 300 ng of total RNA
containing small RNAs was reverse transcribed using the
MegaplexTM RT Primers, Rodent Pool A (Life Technolo-
gies) with the TaqMan R© MicroRNA Reverse Transcrip-
tion Kit and each plate was consecutively run using the
TaqMan R© Universal Master Mix II on the 7900 RT-PCR
system, according to the manufacturer’s instructions. Rel-
ative miRNA abundance determination relied on the as-
sumption that eachmiRNATaqMan R© assay detectedmiR-
NAs with assimilable amplification efficiencies. TheCqs (Cq
= quantification cycle) obtained for eachmiRNAwere used
to directly infer the abundance of each miRNA relative to
that of the most abundant miRNA (miR-222). This was
achieved by subtracting individual Cq values from that ob-
tained for miR-222 (e.g. Cq = Cq miR-21 – Cq miR-222).
The relative level of each miRNA to miR-222 was then in-
ferred using 2(-Cq).
miRNA reverse transcription quantitative real-time poly-
merase chain reaction (RT-qPCR)
Total RNA containing small RNAs was purified from
cultured cells using the miRNeasy kit (Qiagen). miRNA
TaqMan R© assays (Applied Biosystems) for the indicated
miRNAs were used according to the manufacturer’s in-
structions, where 10–30 ng of total RNA was reverse tran-
scribed with pools of miRNA-specific reverse transcription
primers. miRNA levels were determinedwith the TaqMan R©
Universal PCRMasterMix on a 7900RT-PCR system (Life
Technologies), and fold changes in expression were calcu-
lated by the 2−Cq method using U6 snRNA (#001973) as
reference gene.
Luciferase assays
HEK293 cells stably expressing TLR7 or 9 were transfected
with pNF-B-Luc4 reporter (Clontech) with lipofectamine
2000 (Life Technologies), 24–48 h before transfection with
AMOs and TLR ligand stimulation. Following overnight
stimulation with TLR ligand, the cells were lysed in 40 l
(for a 96-well plate) of passive lysis buffer 1× for 20 min
at room temperature. Note that15 l of the lysate was then
subjected to firefly luciferase assay using 40 l of Luciferase
Assay Reagent (Promega). Luminescence was quantified
with a Fluostar OPTIMA (BMG LABTECH) luminome-
ter.
Statistical analyses
Statistical analyses were carried out using Prism 6 (Graph-
Pad Software Inc.). Every experiment was carried out in bi-
ological triplicate, and repeated aminimum of two indepen-
dent times (giving aminimumof six biological values). One-
way and two-way analyses of variance (ANOVA) were used
when comparing groups of conditions, while unpaired one-
tailed t-tests were used when comparing two conditions.
Symbols used: *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ****P
≤ 0.0001 and ‘ns’ is non-significant.
RESULTS
miRNA-independent inhibition of immunostimulatory RNA
sensing by 2′OMe AMO
We have recently reported a positive regulatory role for
miR-19 miRNAs (including both miR-19a-3p and miR-
19b-3p) in the control of nuclear factor kappa B (NF-B)
signalling in several cell lines (27). To investigate the spe-
cific impact of miR-19 inhibition, relative to that of other
members of the same cluster of miRNAs (miR-17-5p, miR-
18a-5p and miR-92a-3p), we measured the inhibition of
TLR7 signalling in primary mouse BMMs treated with spe-
cific 2′OMe AMOs. In agreement with our previous results,
miR-19a-3p inhibition resulted in ∼70% decreased TNF-
production in response to transfected immunostimulatory
ssRNA (B-406AS-1), when compared to the non-2′OMe
control RNA sequence (RD) (Figure 1A). miR-92a-3p in-
hibition also reduced TNF- production by ∼50%, sug-
gesting its involvement in regulating TLR7-mediated im-
mune induction, while miR-18a-5p and miR-17-5p inhi-
bition only had a modest effect on RNA sensing (Fig-
ure 1A). Surprisingly, however, transfection of the non-
targeting control (NC1) 2′OMe AMO resulted in the most
potent inhibition of TNF- production, indicative of an off-
target effect of thismolecule on immunostimulatory ssRNA
sensing. In light of previous reports that 2′OMe RNAs
can act as TLR7 antagonists (10,11), we reasoned that cer-
tain 2′OMe AMO sequences could be more potent than
others––thereby explaining the divergent activity of miR-
18a-5p and NC1 AMOs. To distinguish the direct contri-
bution of miR-19 and -92 in TLR7 sensing from a poten-
tial off-target effect of the 2′OMe AMOs used, experiments
were replicated in BMMs from miR-17∼92flox/flox × LysM-
Cre mice––where levels of mature miR-17-5p, miR-19a-3p
andmiR-92a-3p were decreased by∼70% (Figure 1B). Crit-
ically, pre-treatment with themiR-19a-3p 2′OMeAMO still
reduced TNF- production by ∼50%, suggesting an activ-
ity independent of its miRNA-targeting function (Figure
1A). In accord with the concept of a sequence-dependent
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Figure 1. Off-target effect of 2′OMe AMOs on immunostimulatory RNA sensing. (A) BMMs from WT mice or miR-17∼92flox/flox × LysMCre mice
pre-treated for 45 min with 40 nM of the indicated 2′OMe AMO or non-2′OMe control RNA (RD) were stimulated overnight with 180 nM of im-
munostimulatory ssRNA (B-406AS-1), and TNF- levels were measured in supernatants by ELISA. Percentages of TNF- production compared to the
RD+B-406AS-1 condition are given. The data are averaged from three independent experiments, where each treatment was conducted in biological tripli-
cate. R848 was used as a positive control for induction of TNF-. (B) Total RNA was extracted from non-stimulated BMMs, and miR-17-5p, miR-19a-3p
and miR-92a-3p levels were measured by RT-qPCR. Expression was normalized to U6 RNA and is shown relative to WT mice. Data are averaged from
three independent experiments in biological duplicate. (C) Human PBMCs were pre-treated for 45 min with the indicated dose of AMO or control RNA
(RD), and stimulated overnight with 180 nM of B-406AS-1, and IFN- levels were measured in supernatants by ELISA. The data are averaged from
three independent experiments in different blood donors, where each treatment was conducted in biological triplicate. Percentages of cytokine production
compared to the 0.6 nM RD+B-406AS-1 condition are given. (A and C) Ordinary two-way ANOVA with Dunnett’s multiple comparison tests to the
RD+B-406AS-1 condition are shown. Unless otherwise indicated, differences were not significant. (A–C) SEM is shown.
and miRNA-independent activity of select 2′OMe AMOs
on ssRNA sensing, transfection of 2′OMe NC1 AMO re-
sulted in a dose-dependent inhibition of IFN- production
(indicative of TLR7 recruitment (21,28)) to immunostim-
ulatory ssRNA in human PBMCs, while the miR-18a-5p
2′OMeAMOdid not (Figure 1C). Collectively, these results
support the sequence-dependent inhibition of immunostim-
ulatory RNA sensing by 2′OMe AMOs, independent of
their miRNA-targeting activity.
Sequence-dependent inhibition of immunostimulatory sensing
by 2′OMe AMOs
To define further the modalities of sequence-dependent
TLR7 inhibitory activity of 2′OMe AMOs, a panel of 29
AMOs was screened for their potential effect on TLR7
activation by immunostimulatory ssRNA, in mouse pri-
mary BMMs. To exclude potential miRNA-specific effects,
we performed parallel analyses of these 29 AMOs syn-
thesized with both 2′OMe and LNA/DNA chemistries,
and profiled relative miRNA abundance by low-density
TaqMan R©miRNAmicroarrays (Figure 2). The results from
these experiments could be grouped into four classes of
AMOs: (i) AMOs that had no impact on immunostimu-
latory ssRNA sensing, with either chemistry; (ii) AMOs
that only had an inhibitory effect with the 2′OMe chem-
istry; (iii) AMOs that only had an inhibitory effect with
the LNA/DNA chemistry; and (iv) AMOs that had an
inhibitory effect with both chemistries. Although the in-
hibitory effect of select LNA/DNA AMOs was surprising,
it is consistent with a previous report that phosphoroth-
ioate DNA oligonucleotides can inhibit TLR7 sensing in
a sequence-dependent manner (29). The sequence-specific
and miRNA-independent significant inhibition of im-
munostimulatory ssRNA sensing by 2′OMe AMOs target-
ing miR-195-5p, miR-25-3p, miR-122-5p, miR-200a/b/c-
3p and miR182-5p (Figure 2B) was supported by the lack
of inhibitory activity with LNA/DNA AMOs (Figure 2C),
and the low abundance of thesemiRNAs (less than 100-fold
the level of the most abundant miRNA in BMMs) (Figure
2A).
Sequence-dependent inhibition of human TLR7/8 sensing by
AMOs
To extend these results, we investigated the inhibitory ac-
tivity of the panel of 2′OMe and LNA/DNA AMOs on
TLR7/8 sensing in human PBMCs. The in vitro system us-
ing human PBMCs allows for the analysis of TLR8 acti-
vation, as this function in RNA sensing is not conserved
in mouse BMMs (14). In this model, assessment of TNF-
 production in response to immunostimulatory ssRNAs
reflects TLR8 activation, while IFN- production reflects
TLR7 activation (21,28). In agreement with a TLR8 in-
hibitory activity of select 2′OMeAMOs, TNF- production
was significantly decreased with all seven 2′OMe AMOs
from Class 2 (Figure 3A). Noteworthy, select AMOs from
Classes 1 and 3 (which did not significantly affect TNF-
 production in BMMs) significantly reduced TNF- pro-
duction, suggesting a specific TLR8 inhibitory activity of
these sequences (e.g. 2′OMe AMOs for miR-146a-5p or
miR-331-3p). Nonetheless, there was a significant correla-
tion between the inhibitory activities of the 2′OMe AMOs
onTNF- production in humanPBMCs andmouseBMMs
(r= 0.7145), indicating conservation of the inhibitory activ-
ity of the 2′OMe AMOs between TLR7 and TLR8 (Figure
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Figure 2. Inhibition of immunostimulatory RNA sensing by 2′OMeAMOs is sequence dependent. (A) Total RNA fromBMMs on day 8 post-isolation was
analysed by TaqManR© Array Rodent MicroRNAs in biological duplicate, and miRNA abundance relative to that of the most abundant miRNA––miR-
222––calculated as detailed in theMaterials andMethods section. ND, not detected. BMMs fromWTmice pre-treated with 40 nM of the indicated 2′OMe
AMO (B) or LNA/DNAAMO (C) for 45 min were stimulated overnight with 180 nM of immunostimulatory ssRNA (B-406AS-1), and TNF- levels were
measured in supernatants by ELISA. The RD+B-406AS-1 condition was used as control. The data are averaged from two independent experiments in
biological triplicate. (B and C) Ordinary one-way ANOVA with Dunnett’s multiple comparison tests to the RD+B-406AS-1 condition are shown. Unless
otherwise indicated, differences were not significant. Class 1: AMOs with no inhibitory effect (black bars). Class 2: AMOs with inhibitory effect with
2′OMe chemistry only (light grey bars). Class 3: AMOs with inhibitory effect with LNA/DNA chemistry only (dark grey bars). Class 4: AMOs with
inhibitory effect with both chemistries (white bars). (A–C) SEM is shown.
3A). For LNA/DNA AMOs, the profile of TNF- inhibi-
tion differed notably from that seen in BMMs,with only two
AMOs from Class 3 significantly reducing cytokine pro-
duction (Figure 3B). Consequently, there was no significant
correlation between TNF- inhibition in human PBMCs
andmouse BMMs for LNA/DNAAMOs, suggesting a dif-
ferent activity on TLR7 and TLR8 (Figure 3B). Next, dose-
response studies comparing the activity of highly inhibitory
AMOs (miR-182-5p 2′OMe and miR-331-3p LNA/DNA)
and that of poorly inhibitory AMOs (miR-224-5p 2′OMe
and miR-195-5p LNA/DNA) on both TLR7 and TLR8
sensing were conducted in human PBMCs (Figure 3C and
D). The miR-182-5p 2′OMe AMO had a strong inhibitory
effect on both TNF- and IFN-, and was significantly
more inhibitory than the miR-224-5p 2′OMe AMO in a
dose-dependent manner (Figure 3C). Similar results were
seen with miR-195-5p 2′OMe AMO dose-response stud-
ies (Supplementary Figure S1). In line with a predominant
TLR7 inhibitory effect of LNA/DNAAMOs, themiR-331-
5p LNA/DNA AMO significantly decreased IFN- levels
compared to the miR-195-5p LNA/DNAAMO, while hav-
ing a smaller impact on TLR8-driven TNF- production
(Figure 3D). Given a previous report that the inhibitory ac-
tivity of LNA/DNA AMOs could be related to the phos-
phorothioate (PS) backbone of these molecules (30), we
studied a variant of miR-224-5p 2′OMe synthesized with
a PS backbone (miR-224-5p 2′OMe PS) in human PBMCs.
miR-224-5p 2′OMeAMOwas selected for its low inhibitory
activity, while its LNA/DNA variant significantly inhibited
TLR7 in mouse BMMs (Figure 2). miR-224-5p 2′OMe PS
increased inhibition of TNF- production compared to the
parent phosphodiester molecule (miR-224-5p 2′OMe), sim-
ilar to that of themiR-224-5p LNA/DNAvariant (also syn-
thesized with a PS backbone), in human PBMCs (Supple-
mentary Figure S2A). However, there was no significant im-
pact of the PS backbone on IFN- production, indicating a
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Figure 3. Sequence-dependent inhibition of RNA sensing by 2′OMe AMOs is conserved in human PBMCs. Human PBMCs pre-treated with 40 nM of
the indicated 2′OMe AMO (A) or LNA/DNA AMO (B) for 45 min were stimulated overnight with 180 nM of B-406AS-1. TNF- levels were measured
in supernatants by ELISA. Correlation of relative TNF- production to RD control condition (i.e. inhibitory index) in both human PBMCs and mouse
BMMs is shown for each AMO chemistry (right panels). 2′OMeAMOs of ‘Class 2’ are shown in grey. Correlation for 2′OMeAMOs was highly significant
(P < 0.0001). (C andD) Human PBMCs were pre-treated for 45 min with the indicated dose of AMO or RD, and stimulated overnight with 180 nM of B-
406AS-1. (C andD) TNF- and IFN- levels weremeasured in supernatants by ELISA. (A–D) The data are averaged from aminimumof three independent
experiments in different blood donors, in biological triplicate. Percentages of cytokine production compared to the RD+B-406AS-1 condition (A and B)
or the 0.6 nM RD+B-406AS-1 condition (C and D) are given. Ordinary one-way (A and B) or two-way (C and D) ANOVA with Dunnett’s multiple
comparison tests to the RD+B-406AS-1 (A and B), the miR-224-5p+B-406AS-1 (C) or the miR-195-5p+B-406AS-1 (D) conditions are shown. (A–D)
Unless otherwise indicated, differences were not significant. SEM is shown.
TLR8-specific inhibitory activity of the PS backbone in the
context of this sequence (Supplementary Figure S2A). Col-
lectively, these results suggest that while 2′OMe AMOs can
inhibit both TLR7 and TLR8, LNA/DNA AMOs do not
equally affect these two receptors––with a preferential effect
on TLR7 inhibition, and contribution of the PS backbone
to TLR8 inhibition.
Inhibition of immunostimulatory RNA sensing by 2′OMe
AMOs is governed by a specific motif
We noted that miR-200a-3p, miR-200b-3p and miR-200c-
3p 2′OMe AMOs had a strong inhibitory effect on im-
munostimulatory ssRNA sensing in primary BMMs. Given
their low abundance (Figure 2A), this is likely indepen-
dent of miRNA-targeting activities. Importantly, although
miR-200a-3p and miR-200b-3p had similar inhibitory ac-
tivities, miR-200c-3p was a less potent inhibitor (Figure
2B). These results were confirmed in dose-response stud-
ies in primary BMMs, demonstrating that the miR-200a-
3p 2′OMe AMO was significantly more inhibitory than the
miR-200c-3p AMO (Figure 4A). Similar results were found
with immunostimulatory ssRNA sensing in human PBMCs
on TLR8, where the miR-200c-3p AMO was also signif-
icantly less potent than the miR-200a-3p AMO at reduc-
ing TNF- production (Figure 4B). Notably, as suggested
by their name, these miRNAs belong to the same family
of miRNAs, with strong sequence conservation. Given that
the miR-200b-3p and miR-200c-3p AMOs only differ by
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Figure 4. Inhibition of RNA sensing by 2′OMe is motif dependent. (A) BMMs from WT mice pre-treated with the indicated dose of AMO or RD for
45 min were stimulated overnight with 180 nM of B-406AS-1, and TNF- levels were measured in supernatants by ELISA. The data are averaged from
three independent experiments in biological triplicate. Percentages of cytokine production compared to the 0.6 nM RD+B-406AS-1 condition are given.
Ordinary two-way ANOVA with Dunnett’s multiple comparison tests to miR-200c-3p+B-406AS-1 are shown. (B) Human PBMCs were pre-treated for 45
min with the indicated dose of AMO or RD, and stimulated overnight with 180 nM of B-406AS-1. TNF- levels were measured in supernatants by ELISA.
The data are averaged from three independent experiments in different blood donors, in biological triplicate. Unpaired t-tests comparing miR-200a-3p+B-
406AS-1 and indicated conditions are shown. (C) Top: alignment of miR-200a/b/c-3p AMOs with the core inhibitory motif highlighted in grey. Bottom:
MEME pictogram of the relative frequency of bases constituting the inhibitory motif (40). (D) Alignment of miR-200a-3p, miR-200c-3p, miR-122-5p
and NC1 AMO variants with altered/truncated inhibitory motifs (in 5′-3′ orientation). Native inhibitory motifs are underlined and point mutations are
in red bold. BMMs from WT mice (E, F, G, I) or human PBMCs (F, H) pre-treated with 40 nM of the indicated 2′OMe AMO or RD were stimulated
overnight with 180 nM of B-406AS-1, and TNF- levels were measured in supernatants by ELISA. Percentages of cytokine production compared to the
RD+B-406AS-1 condition are given. The data are averaged from a minimum of two independent experiments, in biological triplicate. Ordinary one-way
ANOVA with Dunnett’s multiple comparison tests to miR-200a-3p+B-406AS-1 (E) or NC1+B-406AS-1 (H and I) are shown. Unpaired t-tests comparing
miR-200a-3p+B-406AS-1 (F) or RD+B-406AS-1 (G) and indicated conditions are shown (ns, not significant). (A, E, H, I) Unless otherwise indicated,
differences were not significant. (A, B and E–I) SEM is shown.
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two bases, we hypothesized that one of these two variations
in the miR-200c-3p AMOwas responsible for the decreased
TLR7-inhibitory activity (Figure 4C). Relying on the vari-
ations between the miR-200a-3p and miR-200b-3p AMOs,
we defined a central core UUACCA sequence changed to
UUACCC in miR-200c-3p, which is potentially directly in-
volved in the inhibitory activity of these 2′OMe AMOs on
TLR7 sensing (Figure 4C). Critically, this core sequence
overlapped with a significantly enriched motif found in all
the inhibitory sequences of Class 2 AMOs previously iden-
tified, in 5′-3′ orientation (for miR-200a/b-3p, and miR-25-
3p) or 3′-5′ orientation (for AMO-NC1, miR-182-5p, miR-
122-5p and miR-195-5p) (Figure 4C and Supplementary
Table S2). To validate the TLR7-inhibitory function of this
motif in the miR-200 2′OMe AMOs, we synthesized two
AMO variants of the miR-200a-3p 2′OMe AMO, with one
(miR-200a-3p mut1) and three (miR-200a-3p mut2) base
changes in the most conserved residues of the enriched mo-
tif (Figure 4C and D). While a single base change in miR-
200a-3p mut1 did not significantly affect the inhibitory ac-
tivity of this 2′OMe AMO, the addition of another two
changes significantly compromised the inhibitory effect of
the miR-200a-3p mut2 2′OMe AMO in primary BMMs
(Figure 4E), thereby underlining a critical role of this motif.
To define further the impact of this motif in the modulation
of TLR7/8 sensing, we generated a set of AMO mutants
and truncated variants (Figure 4D) based on miR-200a/c-
3p, miR-122-5p and NC1 2′OMe AMOs. While the native
miR-200c-3p 2′OMe AMO was significantly less inhibitory
than miR-200a-3p 2′OMe AMO, activity of its mutated
variant miR-200c-3p mut (restoring the core UUACCA se-
quence) did not significantly differ from that of miR-200a-
3p in either human PBMCs or mouse BMMs (Figure 4F).
In addition, truncation of miR-200a-3p 2′OMe AMO to a
shorter form (miR-200a-3p short) directly impacting on the
5′ end of the inhibitory motif, also resulted in decreased in-
hibitory activity of miR-200a-3p in both human and mouse
(Figure 4F). Similar results were found for a 15mer vari-
ant of miR-122–5p (Figure 4G). In addition, multiple vari-
ations of the predicted inhibitory motif in NC1 mut3 sig-
nificantly impacted on the inhibitory activity of 2′OMe
AMO NC1, in both human and mouse (Figure 4H and I).
Nonetheless, NC1 mut3 retained a stronger inhibitory ac-
tivity in human PBMCs than in mouse BMMs, suggesting
that humanTLR8 inhibitionwas less dependent on thismo-
tif than mouse TLR7 (Figure 4H and I). Altogether, these
findings establish the importance of the motif identified in
the inhibitory activity of 2′OMe AMOs on immunostimu-
latory RNA sensing.
Motif-dependent 2′OMe AMO inhibitory activity is TLR7
specific
The above results led us to assess whether base changes to
the poorly inhibitory miR-224-5p 2′OMe AMO, introduc-
ing the consensus inhibitory motif, could increase its in-
hibitory activity on TLR7. Two variants of the miR-224-
5p 2′OMe AMO were synthesized, with one or two base
changes restoring the most highly conserved residues of the
motif otherwise lacking in miR-224-5p (Figure 5A). No-
tably, the miR-224-5p mut2 2′OMe AMO showed an in-
crease in the mFOLD-predicted secondary structure stabil-
ity when compared to the native sequence and the othermu-
tant (mut1) (31). In line with an essential role for the motif
in the inhibitory activity of 2′OMe AMOs, the miR-224-
5p mut2 2′OMe AMO was significantly more inhibitory
than the native sequence on the sensing of two different
immunostimulatory ssRNAs (B-406AS-1 and -Gal-656-
REV) inmouse primary BMMs (Figure 5B). The inhibitory
effect of miR-224-5p mut2 was also seen on TLR8 in hu-
man PBMCs, with reduced TNF- levels compared to the
native 2′OMe AMO (Figure 5C). To confirm the specific
activity of the miR-224-5p mut2 2′OMe AMO variant on
TLR7, the impact of these AMOs was studied in HEK293
cells stably expressing TLR7 or TLR9, and a reporter of
downstream NF-B activity. Noteworthy, HEK293 cells
produce endogenous levels of TLR3, and TLR7-expressing
cells can also be stimulated by polyI:C to trigger TLR3-
dependent NF-B activation. Transfection of the miR-224-
5p mut2 but not the mut1 2′OMe AMO resulted in a sig-
nificantly increased inhibition of NF-B activation by the
chemical TLR7/8 agonist R848 inHEK293 TLR7 cells, but
not with polyI:C treatment, compared to the native miR-
224-5p 2′OMe AMO (Figure 5D). In addition, transfection
of the miR-224-5p mut2 2′OMe AMO had no impact on
TLR9 stimulation by ODN 2006. Collectively, these results
establish the sequence-dependent effect of 2′OMeAMOson
TLR7/8 inhibition, independent of their miRNA-targeting
function.
DISCUSSION
Given their widespread regulatory role in most aspects of
cellular biology, miRNAs present immense therapeutic po-
tential. Since miRNAs can regulate gene networks rather
than specific targets, they have strong biological phenotypes
through their compounded effects on many genes (32). For
example, we recently identified a network of miR-19 tar-
gets converging on the control of inflammation by virtue of
regulating the expression of components of the NF-B sig-
nalling pathway (27). While transfection of exogenous syn-
thetic miRNAs can present the same constraints as small
interfering RNAs regarding off-target effects, the in vivo
application of the two technologies is principally hindered
by delivery and stability issues (33). Conversely, strategies
aimed at blocking miRNAs arguably present greater thera-
peutic potential in the immediate future, as they are based
on highly modified nucleic acids, building on ASO technol-
ogy. This is illustrated with the example of the anti-miR-
122-5p miRNA, miravirsen, a 15-nucleotide LNA/DNA
phosphorothioate AMO with demonstrated therapeutic ef-
fect against hepatitis C virus in recent human clinical trials
(34).
High-affinity ASOs with certain types of modifications,
such as LNA bases, are already known to have hepatotoxic
potential, which is directly dependent on their sequence
and modification pattern (35). It is therefore anticipated
that LNA-containing AMOs will have sequence-dependent
hepatotoxic potential. In contrast, 2′OMe-modified AMOs
do not exhibit the toxicity associated with LNA/DNA
phosphorothioate AMOs, and can be modified at their
ends to block exonuclease activities and increase stabil-
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Figure 5. Motif-dependent activity of 2′OMe AMO is TLR7 specific. (A) mFOLD-predicted structure and free energy (G, in kcal/mol) of miR-224–5p
2′OMeAMOused at 37◦C (31). The bases of the consensus inhibitorymotif are shown in red. Arrows point to mutations introduced in miR-224–5pAMOs
to create the inhibitory motif in miR-224–5p mut2. BMMs from WT mice (B) and human PBMCs (C) pre-treated with 40 nM of the indicated 2′OMe
AMO or RD, were stimulated overnight with 180 nM of B-406AS-1 (B andC) or -Gal-656-REV (B), and TNF- levels were measured in supernatants by
ELISA. (B) The data are averaged from two (for -Gal-656-REV) or three (for B-406AS-1) independent experiments, in biological triplicate. Percentages
of cytokine production compared to the RD+B-406AS-1 (black) or -Gal-656-REV condition (white) are given. (C) The data are averaged from three
independent experiments in different blood donors, in biological triplicate. (D) HEK293 cells stably expressing TLR7 or TLR9 and an NF-B-luciferase
reporter, were transfected with 200 nM of the indicated AMO for 45 min prior to stimulation with R848 (200 ng/ml) (white) or polyI:C (20 g/ml) (grey)
for TLR7 cells, and ODN 2006 (400 nM) (black) for TLR9 cells. Firefly luciferase was assayed after overnight incubation as described in the Materials and
Methods section. Luminescence reads normalized to unstimulated cells (NT) are shown as percentages of the RD+TLR ligand condition. The data are
averaged from aminimum of three independent experiments in biological triplicate. (B–D) Ordinary one-way ANOVAwith Dunnett’s multiple comparison
tests to the miR-224–5p+B-406AS-1 condition are shown. Unless otherwise indicated, differences were not significant. SEM is shown.
ity in serum (7,36–37). Such modifications can include
the use of double-stranded RNA flanking regions (36)
or chemical modifications, such as phosphorothioate or
the recently reported N,N-diethyl-4-(4-nitronaphthalen-1-
ylazo)-phenylamine (ZEN) (7,37). With the observation
that 2′OMe modification could be used to ablate TLR7/8
activation by synthetic RNAs (11,38), 2′OMe incorpora-
tion in synthetic RNAs has the significant added advantage
of abrogating the potential off-target activation of innate
immunity by RNA AMOs, which would otherwise induce
TLR7/8 in a sequence-dependent manner. Importantly, al-
though two reports have previously indicated that the in-
hibitory activity of 2′OMemodifications could be sequence
dependent (with 2′OMe cytidine residues having no signif-
icant inhibitory activity) (10,22), there are no accounts re-
garding the activity of different sequences of fully 2′OMe-
modified RNA on other immunostimulatory RNAs.
In this work, we originally set out to study the role
of the individual members of the miR-17∼92 cluster of
miRNAs (miR-17/20a, miR-19a/b, miR-18a and miR-
92a) on TLR7-driven NF-B signalling in mouse primary
macrophages. In accord with our previous findings (27),
we demonstrated that 2′OMe AMO-mediated blocking of
miR-19 significantly reduced the production of TNF- in-
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duced by immunostimulatory ssRNA in WT BMMs. How-
ever, this effect of the miR-19a-3p 2′OMe was mostly re-
tained in BMMs depleted of miR-19a-3p and miR-19b-
3p, indicative of a miRNA-independent effect (Figure 1).
In addition, we observed a strong off-target effect of the
non-targeting control 2′OMe AMO on TNF- production
(Figure 1). Taken together with our later observations that
targeting of the liver-specific miR-122-5p or poorly abun-
dant miR-195-5p, miR-25-3p, miR-200a/b/c-3p, miR182-
5p and the mutant miR-224-5p mut2 by 2′OMeAMOs (but
not their LNA/DNA AMO counterparts) also resulted in
significant inhibition of immunostimulatory ssRNA sens-
ing, our work establishes sequence-dependent andmiRNA-
independent off-target inhibitory activity of 2′OMe AMOs
on the immune sensing of pathogenic RNA by human
and mouse phagocytes. The inhibitory effect was dose de-
pendent, with a maximum IC50 around 2 nM for miR-
195-5p 2′OMe AMO (Supplementary Figure S1), while
other 2′OMe AMOs (for example, miR-224-5p, not shown)
showed only minor inhibitory activity when used at concen-
trations as high as 80 nM. Given the molarity of immunos-
timulatory ssRNA used in our experiments (at 180 nM),
the results suggest that these specific sequences are active
at 1/90th of stimulatory ssRNA concentration, in line with
the findings of others (13).
DOTAP-mediated transfection of immunostimulatory
RNA sequences in mouse BMMs instigates a TLR7-
dependent TNF- production, as evidenced by a lack of
response in cells from TLR7-deficient mice (20–21,39). To
directly implicate TLR7 in sequence-dependent activity of
2′OMe AMOs, we further demonstrated that NF-B acti-
vation was impaired by an inhibitory variant of miR-224-
5p 2′OMe AMO, in HEK293 TLR7 cells stimulated with
the TLR7/8 chemical agonist R848. This effect of selected
2′OMeAMOs was specific to TLR7 and was not seen when
theHEK293 TLR7 cells were stimulated with the TLR3 lig-
and polyI:C, or in HEK293 TLR9 cells stimulated with a
TLR9 agonist. Importantly, we also observed inhibitory ac-
tivity with the native miR-224-5p 2′OMe in HEK293 TLR7
cells, with doses ≥200 nM. We anticipate that high doses
of most 2′OMe AMOs will antagonize TLR7 sensing, in-
dependent of the sequence used. However, even at 200–400
nM, miR-224-5p mut2 had a stronger inhibitory effect on
TLR7 than the native miR-224-5p AMO (Figure 5 and not
shown), underlining detectable sequence-dependent effects
between AMOs used at high doses.
While comparing the effects of miR-200 AMO variants,
we noted that miR-200c-3p had a lesser capacity to inhibit
TNF- production, compared to miR-200a-3p and miR-
200b-3p. Given the similarity of the sequences, we were able
to identify a central region (UUACCA) that was not con-
served inmiR-200c-3p and could be at play in the inhibitory
activity of these molecules. Critically, we found this motif
in miR-182-5p and miR-122-5p AMOs, when read in 3′-
5′ orientation. Relying on Multiple Em for Motif Elicita-
tion (MEME) analysis of the inhibitory 2′OMe AMO se-
quences of Class 2 in either 5′-3′ or 3′-5′ orientation (40),
we demonstrated that they all contained a longer motif de-
rived from this UUACCA (Figure 4 and Supplementary
Table S2). Mutation or deletion of part of this motif re-
sulted in the loss of inhibitory activity for miR-200a-3p,
miR-122-5p and NC1 2′OMe AMO variants, while intro-
duction of this motif to the poorly inhibitory miR-224-
5p AMO significantly increased the inhibitory activity of
the AMO on TLR7. These results clearly demonstrate the
sequence-dependent effects of 2′OMe AMOs, and indicate
that the motif identified could be used to predict the in-
hibitory potential of 2′OMe AMOs. In this regard, enrich-
ment analysis of the identified motif in AMOs targeting
all human miRNAs in miRBaseV20 (in both 5′-3′ and 3′-
5′ orientations) (41), identified 53 AMOs that are possibly
highly inhibitory (Supplementary Table S3). Interestingly,
miR-27a-3p and miR-301a-3p AMOs belong to this list of
potential inhibitors. Although we did find miR-27a-3p to
significantly inhibit TLR8 in human PBMCs, our experi-
mental evidence does not support a strong inhibitory ac-
tivity for miR-301a-3p in either mouse or human models.
We speculate that this relates to the position of the motif
at the 5′-end of the sequence, which precludes formation of
secondary structures necessary for inhibitory activity; sim-
ilar to what is seen with miR-122-5p short. Nonetheless,
our predictions likely underrepresent the sum of inhibitory
2′OMeAMO sequences, as it only considers sequences with
a close relationship to the motif (P < 0.001) and changing
the stringency of prediction to P < 0.01 results in the se-
lection of more than 500 AMOs. Furthermore, we antic-
ipate that other inhibitory motifs exist. As such, none of
the miRNAs present in Class 4, which were able to inhibit
TLR7 in both 2′OMe and LNA/DNA chemistries, had the
inhibitory motif, albeit most likely resulting from miRNA-
independent activities. Indeed, while miR-19a-3p did not
have the predicted highly inhibitory motif, it was able to
repress TLR7 sensing independently of miR-19 targeting
in miR-19-deficient cells (Figure 1). Moreover, microarray
profiling of mRNA expression in BMMs after DOTAP-
mediated LNA/DNA AMO transfection (for miR-19a-3p,
miR-15a-5p and miR-34a-5p) did not result in a significant
de-repression of genes targeted by these miRNAs accord-
ing to specific hexamer enrichment analyses with DIANA-
mirExtra (42) (data not shown). These results indicate that
DOTAP-mediated transfection of AMOs inefficiently deliv-
ers them to the cytoplasm,while favouring endosomal deliv-
ery (20,43), thus pointing to miRNA-independent activities
for Class 3 and 4 AMOs.
Although our predictions might be useful in identifying
2′OMe AMOs with greater TLR7 inhibitory activity, it is
most likely that other parameters, including the secondary
structure of the AMOs, also directly influence their activ-
ity. As shown in Figure 5, miR-224-5p mut2 AMO is more
stable than the native miR-224-5p and miR-224-5p mut1
AMOs, and displayed the strongest TLR7 inhibitory ac-
tivity. Given that 2′OMe RNAs have a strong affinity to
TLR7 (13), it is reasonable to assume that the rules regu-
lating their TLR7 activity are similar to that of immunos-
timulatory ssRNA, and that structure has an impact (20–
21,44). We have previously shown that immunostimulatory
motifs embedded in RNA with double-stranded regions
were more potent activators of TLR8 (20,21). It can be
speculated that the activity of 2′OMe inhibitory motifs is
also partially dependent on surrounding sequences forming
double-stranded structures. As such, a commercial 2′OMe
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AMO scaffold containing double-stranded 5′- and 3′-end
loops might have increased inhibitory activity on TLR7/8
(36). Our analyses of truncated variants of miR-122-5p and
miR-200a-3p 2′OMe AMOs also show that disruption of
the context of the inhibitory motif can significantly reduce
its activity (Figure 4). The miR-122-5p AMO (reported as
‘15mer 2′OMe 5′inZEN, 3′ZEN’) was previously found to
have similar miR-122–5p inhibitory activity in reported as-
says, compared to its full-length counterpart (7). Although
the use of short 2′OMeAMOs should be optimized tomake
sure they retain most of their inhibitory activity (7), this ap-
proach could therefore help to limit secondary structure and
motifs with inhibitory activity on TLR7 sensing.
We also observed significant inhibition of immunostimu-
latory ssRNA sensing by select LNA/DNA phosphoroth-
ioate AMOs from Classes 3 and 4. Although miRNA-
based mechanisms could be at play for LNA/DNA AMOs
targeting abundant miRNAs (such as miR-191-5p, miR-
16-5p, miR-29a-3p or miR-100-5p), such effects can be
ruled out for other AMOs of Class 3 targeting poorly
abundant miR-224-5p, miR-331-3p, miR-134-5p or miR-
31-5p. SuchmiRNA-independent TLR7 inhibition by these
LNA/DNA phosphorothioate AMOs is rather in line with
previous studies that reported the specific inhibition of
R848 and immunostimulatory ssRNA-driven TLR7 acti-
vation, by phosphorothioate DNA oligonucleotide (ODN)
in human HEK293 TLR7 cells and in mouse spleno-
cytes (29,30). The TLR7-inhibitory activity of ODNs
was much more potent with a phosphorothioate back-
bone than with a phosphodiesterase one (30), and was
sequence dependent (29). Critically, a specific TLR7 in-
hibitory ODN (IRS661) substantially reduced immune re-
sponses to influenza virus, dengue-2 virus and bacterial
tRNA (17,29,45). In our work, we confirm the sequence-
dependent effect of LNA/DNA phosphorothioate AMOs
on TLR7 in both human PBMCs (through modulation
of IFN- levels) and mouse BMMs. However, unlike for
2′OMe AMOs, we were not able to identify enriched mo-
tifs controlling the sequence-dependent inhibitory activity
of LNA/DNA AMOs on TLR7. There was little overlap
between the inhibition of TLR7 in mouse and that of TLR8
in human PBMCs, indicating different modes of action of
LNA/DNA AMOs for each receptor. Our data also sug-
gest a direct contribution for the phosphorothioate back-
bone in the sequence-dependent inhibition of TLR8 (Sup-
plementary Figure S2A).
Collectively, our findings underline a potential for misin-
terpretation of results from experiments usingAMOs aimed
at defining the role of specific miRNAs in responses involv-
ing the innate immune system. This is of particular con-
cern when using in vivo injection of naked or liposome-
encapsulated AMOs, which encounter phagocytes express-
ing TLR7/8. Noteworthy, we found that miR-200a-3p and
NC1 2′OMeAMOvariants conjugated with a 3′ cholesterol
group (commonly used for in vivo administration and re-
ferred to as antagomiRs (4)) were also strong inhibitors of
TLR7/8, withmarginally less activity than native sequences
(Supplementary Figure S2B). Importantly, 2′OMe modifi-
cations have been shown to inhibit other innate immune
sensors and effectors, including MDA5 or IFN-induced
proteins with tetratricopeptide repeats (46,47). It is there-
fore very likely that 2′OMe AMOs will also interfere with
the normal function of these innate immune regulators, in
addition to their inhibitory role on TLR7/8 described here.
Furthermore, our results suggest that sequence-dependent
TLR7 inhibition by AMOs is not restricted to 2′OMe
AMOs, and can also be seen with LNA/DNA phospho-
rothioate AMOs. Given the therapeutic potential of these
molecules, a thorough characterization of their inhibitory
off-target effects on the immune system is required to ensure
minimal unintended immune suppression to avoid sensitiz-
ing of patients to intercurrent viral and bacterial infections.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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